{"id":"NCT00713830","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","officialTitle":"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2011-01","completion":"2011-01","firstPosted":"2008-07-14","resultsPosted":"2016-12-14","lastUpdate":"2016-12-14"},"enrollment":859,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClik®"]},{"type":"DRUG","name":"Sulfonylurea","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to sulfonylurea without or with metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide when added to sulfonylurea with or without metformin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than (\\<) 7 percent (%); percentage of patients reaching HbA1c less than or equal to (\\<=) 6.5%; body weight; fasting plasma glucose (FPG); beta-cell function assessed by homeostasis model assessment (HOMA) beta; 2-hour postprandial plasma glucose (PPG), glucagon, insulin, proinsulin, and C-peptide after a standardized meal challenge test in a sub-study in all patients in selected centers; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.1,"sd":0.071},{"arm":"Lixisenatide","deltaMin":-0.85,"sd":0.061}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":31},"locations":{"siteCount":16,"countries":["United States","Bulgaria","Czechia","Egypt","Germany","India","Israel","Japan","Netherlands","Romania","Russia","South Korea","Taiwan","Thailand","Tunisia","Turkey (Türkiye)"]},"refs":{"pmids":["24650952","27319011","27267268","27252787"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":285},"commonTop":["Hypoglycaemia","Nausea","Nasopharyngitis","Diarrhoea","Dizziness"]}}